Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DENVER , May 14, 2024 /PRNewswire/ -- Today, DaVita (NYSE: DVA) published its 2023 Community Care Report, underscoring its dedication to corporate social responsibility and commitment to setting a new standard for health care services. DaVita's annual Community Care Report examines progress toward its 2025 Environmental, Social, and Governance (ESG) goals to help improve the lives of patients and support the health of communities globally.

DaVita Celebrates Corporate Citizenship Achievements with Release of 2023 Community Care Report

Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER , May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms.

DaVita Appoints New Chief Information Officer

Alphabet

Garmin

Minerals Technologies

DaVita (DVA), Minerals Technologies (MTX), Alphabet (GOOGL) and Garmin (GRMN) have been selected as the momentum picks for the day using the Driehaus strategy.

4 Must-Buy Momentum Stocks Banking on the Driehaus Strategy

DENVER , May 9, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at BofA Securities 2024 Health Care Conference on Tuesday, May 14th, 2024 at 5:00 pm Pacific Daylight Time. To view the live webcast, visit the BofA page and create a free registration.

DaVita Inc. to Participate in the BofA Securities 2024 Health Care Conference

Award celebrates excellence in nursing, underscoring the kidney care provider's commitment to recognizing the indelible impact of clinicians on outstanding patient care DENVER , May 9, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that 54 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week. The award is part of The DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 6,500 health care facilities nationwide.

DaVita Honors 54 Nephrology Nurses with DAISY Awards

Encompass Health

Option Care Health

Pennant Group Inc

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.

4 Stocks to Buy in a Thriving Outpatient Home Health Industry

Addus HomeCare

We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.

Top 5 Outpatient and Home Healthcare Stocks for Solid Returns

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy?

Dream Finders Homes

Pilgrim's Pride

Root

Super Micro Computer

ROOT, SMCI, PPC, DFH and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2024.

New Strong Buy Stocks for May 6th

Belden

DFH, DVA and BDC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 6, 2024.

Best Value Stocks to Buy for May 6th

DaVita's (DVA) robust segmental revenues drive its first-quarter performance.

DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up

DaVita Inc. (NYSE:DVA ) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Andrew Mok - Barclays Pito Chickering - Deutsche Bank Kevin Fischbeck - Bank of America Dean Rosales - Wolfe Research Gary Taylor - Cowen A.J. Rice - UBS Lisa Clive - Bernstein Operator Good evening.

DaVita Inc. (DVA) Q1 2024 Earnings Call Transcript

DaVita HealthCare (DVA) came out with quarterly earnings of $2.38 per share, beating the Zacks Consensus Estimate of $1.96 per share. This compares to earnings of $1.58 per share a year ago.

DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates

DaVita raised its annual profit forecast on Thursday banking on strong demand for its kidney dialysis services, sending its shares up 3.7% in trading after the bell.

DaVita gains after upbeat quarterly profit prompts annual forecast raise

DENVER , May 2, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2024. "Through the first quarter, we continued building on the momentum generated through 2023, demonstrating operational discipline while continuing to find opportunities to invest, innovate and most importantly deliver clinical excellence," said Javier Rodriguez, CEO of DaVita Inc. Financial and operating highlights for the quarter ended March 31, 2024: Consolidated revenues were $3.071 billion.

DaVita Inc. 1st Quarter 2024 Results

Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the first quarter.

Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings

Organon & Co

Roivant Sciences Ltd

Finding firms with strong growth potential is essential for healthcare investors looking for large profits. Three exceptional firms have surfaced as strong healthcare stocks.

3 Healthcare Stocks With the Potential to Triple Your Investment by 2026

Nu Holdings

Mitsubishi is a stock Buffett plans to own "indefinitely" and is his biggest winner year to date. Nu Holdings continues to grow by leaps and bounds in Latin America.

Warren Buffett's 3 Best-Performing Stocks So Far in 2024: Are They Buys Now?

HCA Healthcare

Intuitive Surgical

The healthcare industry is one of the biggest in the United States and other countries. In the US, the total Medicare expenditure stood at over $927 billion in 2022 and the trend is continuing as the population ages.

Best blue chip healthcare stocks to buy and hold in 2024

Recently, Zacks.com users have been paying close attention to DaVita HealthCare (DVA). This makes it worthwhile to examine what the stock has in store.

Is Trending Stock DaVita Inc. (DVA) a Buy Now?

Kidney care provider enters virtual power purchase agreement in Spain after reaching 100% renewable energy goal in its North American operations DENVER , April 22, 2024  /PRNewswire/ -- By 2025, DaVita (NYSE: DVA), a leading provider of kidney care services, expects to match 100% of its electricity use across its global operations with renewable energy purchases. DaVita has contracted with ACCIONA Energía on a virtual power purchase agreement (PPA) facilitating the development of clean energy projects in Spain.

DaVita's Global Operations Powered by 100% Renewable Energy

DENVER , April 17, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 2, 2024, at 5:00 p.m. Eastern Time.

DaVita Inc. Schedules 1st Quarter 2024 Investor Conference Call

Just this morning, the CPI data reported a notable and surprise increase in the rate of inflation. Although disinflationary pressure have been strong since early 2023, it seems those forces have reversed, and policymakers may have to deal with the changing expectations.

Market Jitters: 2 Top Ranked Stocks for Defensive Positioning

Zacks.com users have recently been watching DaVita HealthCare (DVA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Most-Watched Stock DaVita Inc. (DVA) Worth Betting on Now?

DENVER , April 10, 2024 /PRNewswire/ -- DaVita Inc. today announced that its Board of Directors has appointed a new independent director, Dennis Pullin, to join the Board, effective April 10, 2024. "We're pleased to welcome Dennis to DaVita's board," said Pamela Arway, independent chair of the DaVita Inc. Board of Directors.

News for DaVita Stock (DVA)